Burmester, G R.(2016). Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Annals of the Rheumatic Diseases, 75(1), 68-74. doi:10.1136/annrheumdis-2015-207281
MLA ZitierstilBurmester, Gerd R. "Efficacy and Safety of Subcutaneous Tocilizumab Versus Intravenous Tocilizumab in Combination With Traditional DMARDs in Patients With RA At Week 97 (SUMMACTA)". Annals of the Rheumatic Diseases, 75.1 ( 2016 ): 68-74.
Bitte überprüfen Sie diese Angaben auf Richtigkeit, bevor Sie sie in Ihre Arbeit aufnehmen.